The South San Francisco company will ask the FDA if "encouraging" results from a mid-stage study — powering an 88 percent leap in its stock price — is enough to jump into a pivotal Phase III trial......»»

Lilly's Eli Lilly and Company (LLY) announced that its key pipeline candidate, solanezumab, failed to meet the primary endpoint in a phase III study (EXPEDITION3) in patients with mild Alzheimer's dementia.
Lilly’s Eli Lilly and Company L.....»»

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock jumped as high as 24.89% during the early trading hours today, after the company reported the results from its pivotal inTandem1 Phase 3 trial of Sotagliflozin, which is a treatment for diabetes. The study.....»»